APELLIS PHARMACEUTICALS, INC.
APLSUnited States
35 filed reports · 453 financial concepts
Latest figures
Group totals as stated in the company’s own filed reports, each with a link to its report. The change is against the same period a year earlier.
| Figure | Latest fiscal year | Latest quarter |
|---|---|---|
| Revenue | $1BFY2025 · to Dec 31, 2025+28.5% from $781M10-K | $268MQ1 FY2026 · to Mar 31, 2026+60.9% from $167M10-Q |
| Net income | $22.4MFY2025 · to Dec 31, 2025a year earlier: -$198M10-K | $18.7MQ1 FY2026 · to Mar 31, 2026a year earlier: -$92.2M10-Q |
| Operating income | $55.4MFY2025 · to Dec 31, 2025a year earlier: -$165M10-K | $26.5MQ1 FY2026 · to Mar 31, 2026a year earlier: -$83.3M10-Q |
Filed reports
35 reports · Sep 2017 to Mar 2026Each report counts once it has at least one extracted financial fact.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 26 | 3,153 | Sep 2017 to Mar 2026 |
| Annual · 10-KSEC EDGAR | 8 | 2,960 | Dec 2017 to Dec 2025 |
| Annual · 10-K/ASEC EDGAR | 1 | 392 | Dec 2023 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2026 Q1 | 10-Q | Mar 31, 2026 | May 7, 2026 | 321 | Open |
| FY2025 | 10-K | Dec 31, 2025 | Feb 24, 2026 | 793 | Open |
| FY2025 Q3 | 10-Q | Sep 30, 2025 | Oct 30, 2025 | 234 | Open |
| FY2025 Q2 | 10-Q | Jun 30, 2025 | Jul 31, 2025 | 188 | Open |
| FY2025 Q1 | 10-Q | Mar 31, 2025 | May 7, 2025 | 124 | Open |
| FY2024 | 10-K | Dec 31, 2024 | Feb 28, 2025 | 401 | Open |
| FY2024 Q3 | 10-Q | Sep 30, 2024 | Nov 5, 2024 | 144 | Open |
| FY2024 Q2 | 10-Q | Jun 30, 2024 | Aug 1, 2024 | 117 | Open |
| FY2024 Q1 | 10-Q | Mar 31, 2024 | May 7, 2024 | 123 | Open |
| FY2023 | 10-K/A | Dec 31, 2023 | Feb 29, 2024 | 392 | Open |
| FY2023 Q3 | 10-Q | Sep 30, 2023 | Nov 1, 2023 | 160 | Open |
| FY2023 Q2 | 10-Q | Jun 30, 2023 | Jul 31, 2023 | 135 | Open |
Financial data
453 concepts · 6,505 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial433 concepts · 6,214 facts · Dec 2015 to Mar 2026
- Net income loss52 · Dec 2015 to Mar 2026
- Operating income loss52 · Dec 2015 to Mar 2026
- Cash and cash equivalents at carrying value51 · Dec 2015 to Mar 2026
- Antidilutive securities excluded from computation of earnings per share amount50 · Dec 2015 to Mar 2026
- Increase decrease in accounts payable49 · Dec 2015 to Mar 2026
- Increase decrease in accrued liabilities49 · Dec 2015 to Mar 2026
- Other nonoperating income expense49 · Sep 2016 to Mar 2026
- Research and development expense49 · Sep 2016 to Mar 2026
- Share based compensation49 · Dec 2015 to Mar 2026
- Stockholders equity (US GAAP)48 · Dec 2015 to Mar 2026
- Cash cash equivalents restricted cash and restricted cash equivalents47 · Dec 2015 to Mar 2026
- Common stock par or stated value per share47 · Dec 2016 to Mar 2026
- Accounts payable current46 · Dec 2016 to Mar 2026
- Accrued liabilities current46 · Dec 2016 to Mar 2026
- Accrued Payroll Liabilities Current46 · Dec 2016 to Mar 2026
- Accrued Research And Development Current46 · Dec 2016 to Mar 2026
- Additional paid in capital46 · Dec 2016 to Mar 2026
- Assets46 · Dec 2016 to Mar 2026
- Assets current46 · Dec 2016 to Mar 2026
- Common stock shares authorized46 · Dec 2016 to Mar 2026
- Common stock shares issued46 · Dec 2016 to Mar 2026
- Common stock shares outstanding46 · Dec 2016 to Mar 2026
- Common stock value46 · Dec 2016 to Mar 2026
- Increase decrease in other noncurrent assets46 · Dec 2015 to Mar 2026
Segment12 concepts · 156 facts · Dec 2022 to Mar 2026
- Employee benefits and share based compensation13 · Dec 2022 to Mar 2026
- External Commercial Costs13 · Dec 2022 to Mar 2026
- External General and Administrative Costs13 · Dec 2022 to Mar 2026
- External Research and Development Costs13 · Dec 2022 to Mar 2026
- Income tax expense benefit13 · Dec 2022 to Mar 2026
- Interest expense nonoperating13 · Dec 2022 to Mar 2026
- Internal Research and Development Costs13 · Dec 2022 to Mar 2026
- Internal Selling, General and Administrative Cost13 · Dec 2022 to Mar 2026
- Investment income nonoperating13 · Dec 2022 to Mar 2026
- Net income loss13 · Dec 2022 to Mar 2026
- Revenue13 · Dec 2022 to Mar 2026
- Segment reporting other item amount13 · Dec 2022 to Mar 2026
Product6 concepts · 127 facts · Sep 2020 to Mar 2026
- Revenue96 · Sep 2020 to Mar 2026
- Royalty expense25 · Dec 2022 to Mar 2026
- Annual Sales2 · Mar 2026
- Contingent Value Right Bonus Cash Payable Per Share upon Achievement of Sales Milestone2 · Mar 2026
- Regulatory Milestone Accrued Based on Achievement1 · Dec 2023
- Regulatory Milestone Incurred Based On Achievement1 · Dec 2023
Geography2 concepts · 8 facts · Dec 2015 to Mar 2020
- Operating lease expense6 · Dec 2015 to Dec 2018
- Monthly Lease Payment2 · Dec 2019 to Mar 2020
Segments
291 factsFigures broken down by business line, region, product or another axis the company reports on.
Statement business segments1 member · 156 facts
- Reported Segment [Member]156 · Dec 2022 to Mar 2026
Product or service9 members · 127 facts
- SYFOVRE [Member]30 · Mar 2023 to Mar 2026
- Product [Member]29 · Sep 2020 to Mar 2026
- Licensing and other revenue [Member]27 · Sep 2020 to Mar 2026
- EMPAVELI [Member]22 · Dec 2021 to Mar 2026
- EMPAVELI and Aspaveli [Member]13 · Dec 2022 to Mar 2026
- Sales Revenue Tranche One2 · Mar 2026
- Sales Revenue Tranche Two2 · Mar 2026
- Collaboration [Member]1 · Dec 2020
- License [Member]1 · Dec 2020
Statement geographicalsrt:StatementGeographicalAxis2 members · 5 facts
- Waltham, Massachusetts [Member]3 · Dec 2016 to Dec 2018
- Watertown, Massachusetts [Member]2 · Dec 2019 to Mar 2020
Statement geographicalus-gaap:StatementGeographicalAxis1 member · 3 facts
- San Francisco, California [Member]3 · Dec 2015 to Dec 2017
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
No commentary or risk-factor text for this company.
Earnings calls
Transcripts with management claims and analyst questions, one per fiscal period.
No earnings-call transcripts for this company.
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Ask about this company in your AI model
Connect FactIQ to Claude, ChatGPT or another AI model (how to install), then paste this prompt.
Use FactIQ to get the revenue, net income and operating income of APELLIS PHARMACEUTICALS, INC. (APLS) from its filed reports, for the last five fiscal years and the latest quarter or half year. Link each figure to its filing, and chart the trend.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Nov 16, 2026) and refreshed every few hours.